BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16720832)

  • 1. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia.
    Nurden P; Debili N; Vainchenker W; Bobe R; Bredoux R; Corvazier E; Combrie R; Fressinaud E; Meyer D; Nurden AT; Enouf J
    Blood; 2006 Oct; 108(8):2587-95. PubMed ID: 16720832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of thrombocytopenia in platelet-type von Willebrand disease.
    Bury L; Malara A; Momi S; Petito E; Balduini A; Gresele P
    Haematologica; 2019 Jul; 104(7):1473-1481. PubMed ID: 30655369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B.
    Nurden P; Gobbi G; Nurden A; Enouf J; Youlyouz-Marfak I; Carubbi C; La Marca S; Punzo M; Baronciani L; De Marco L; Vitale M; Federici AB
    Blood; 2010 Apr; 115(13):2649-56. PubMed ID: 20118404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered megakaryocytopoiesis in von Willebrand type 2B disease.
    Nurden AT; Federici AB; Nurden P
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():277-81. PubMed ID: 19630816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
    Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
    Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.
    Slayton WB; Patel M; Sola-Visner M; Harris N; Rivers A; Montgomery RR; Friedman KD
    J Pediatr Hematol Oncol; 2008 Sep; 30(9):708-11. PubMed ID: 18776767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
    Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
    Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma.
    Takimoto Y; Imanaka F
    Int J Hematol; 1999 Aug; 70(2):127-31. PubMed ID: 10497852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
    Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
    Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S; Conard J; Samama MM; Dellagi K
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model.
    Poujol C; Ware J; Nieswandt B; Nurden AT; Nurden P
    Exp Hematol; 2002 Apr; 30(4):352-60. PubMed ID: 11937271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val.
    Doggett TA; Girdhar G; Lawshe A; Miller JL; Laurenzi IJ; Diamond SL; Diacovo TG
    Blood; 2003 Jul; 102(1):152-60. PubMed ID: 12637314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.